Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

ATP Driven Pumps I: An Overview01:27

ATP Driven Pumps I: An Overview

9.9K
ATP-driven pumps, also known as transport ATPases, are integral membrane proteins. They have binding sites for ATP located on the membrane's cytosolic side and the ion-conducting domain in the transmembrane region. These pumps use the free energy released from ATP hydrolysis to move the solutes across cell membranes against an electrochemical gradient.
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
9.9K
Xylem and Transpiration-driven Transport of Resources02:03

Xylem and Transpiration-driven Transport of Resources

26.9K
The xylem of vascular plants distributes water and dissolved minerals that are taken up by the roots to the rest of the plant. The cells that transport xylem sap are dead upon maturity, and the movement of xylem sap is a passive process.
26.9K
ATP Driven Pumps II: P-type Pumps01:34

ATP Driven Pumps II: P-type Pumps

6.5K
The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V.
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
6.5K
Microtubule Associated Proteins (MAPs)01:42

Microtubule Associated Proteins (MAPs)

6.0K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
6.0K
Plotting of Topographic Maps01:29

Plotting of Topographic Maps

551
Topographic maps represent the Earth's surface features using contour lines, which connect points of equal elevation to create a two-dimensional representation of three-dimensional terrain. Creating a topographic map requires a systematic approach.Begin by plotting a scaled grid and marking intersections corresponding to the survey's elevation data points. Assign elevation values at these intersections to build the base map. Next, determine contour levels using a consistent contour interval,...
551
Coordinates and Map Projections01:29

Coordinates and Map Projections

630
Coordinates and map projections are essential tools in accurately representing the Earth's surface for various applications, ranging from navigation to spatial analysis. The latitude and longitude coordinate system is a universally recognized framework for defining locations. Latitude specifies the distance of a point north or south of the equator, measured in degrees from 0° at the equator to 90° at the poles. Longitude indicates a location's position east or west of the prime meridian,...
630

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the role of pretraining dataset size and diversity on single-cell foundation model performance.

Nature methods·2026
Same author

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

Nature cancer·2026
Same author

Scalable nonparametric clustering with unified marker gene selection for single-cell RNA-seq data.

Cell reports methods·2026
Same author

BRCA1-A and LIG4 complexes mediate ecDNA biogenesis and cancer drug resistance.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Chromosomal instability and chromosome 17p loss drive convergent <i>NDE1</i> synthetic lethality in metastatic cancer cells.

bioRxiv : the preprint server for biology·2026
Same author

Improving atlas-scale single-cell annotation models with hierarchical cross-entropy loss.

Nature computational science·2026
Same journal

Itaconate in cancer immunity: Evidence, ambiguities, and translational barriers.

Trends in cancer·2026
Same journal

Patient-derived organoids in hematologic malignancies: Fidelity and translation beyond animals.

Trends in cancer·2026
Same journal

Precision neuro-oncology for children: Time to gear up!

Trends in cancer·2026
Same journal

Multi-omics analysis of extracellular vesicle cargo in cancer.

Trends in cancer·2026
Same journal

An immunological panacea for cancer-related cachexia.

Trends in cancer·2026
Same journal

Beyond one gene, one target: Next-generation precision oncology.

Trends in cancer·2026
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast
09:34

Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast

Published on: March 30, 2010

17.3K

Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.

Peter S Winter1, Kris C Wood2

  • 1Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA; Program in Genetics and Genomics, Duke University, Durham, NC, USA; Current address: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Trends in Cancer
|May 1, 2018
PubMed
Summary
This summary is machine-generated.

Scientists identified two KRAS-mutant cancer subtypes by linking KRAS effectors to phenotypes. This approach reveals distinct effector landscapes and potential therapeutic vulnerabilities in diverse cancers.

Keywords:
KRASRNAiRSKdependency

More Related Videos

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

6.0K
A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells
10:37

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

Published on: August 22, 2025

1.3K

Related Experiment Videos

Last Updated: Feb 11, 2026

Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast
09:34

Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast

Published on: March 30, 2010

17.3K
Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

6.0K
A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells
10:37

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

Published on: August 22, 2025

1.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Oncogenic KRAS mutations are key drivers of cancer progression.
  • KRAS activates multiple effector pathways, but their specific roles in oncogenesis and tumor heterogeneity are unclear.

Purpose of the Study:

  • To functionally link KRAS effector pathways to specific oncogenic phenotypes.
  • To investigate the heterogeneity of KRAS-mutant cancers and identify distinct subtypes.

Main Methods:

  • Utilized a combinatorial small interfering RNA (siRNA) screening approach.
  • Applied the method across a large panel of cancer cell lines to assess KRAS effector functions.

Main Results:

  • Identified two major subtypes of KRAS-mutant cancers.
  • Characterized distinct effector pathway landscapes for each subtype.
  • Uncovered specific therapeutic vulnerabilities associated with each subtype.

Conclusions:

  • The study provides a novel framework for dissecting KRAS signaling networks.
  • Reveals subtype-specific dependencies that could inform targeted cancer therapies.
  • Highlights the importance of understanding tumor heterogeneity for effective treatment strategies.